Condition: Malignant Melanoma Stage III · Sponsor: Hildur Helgadottir
At present two studies (SWOG S1801 and NADINA) have demonstrated superiority when using neoadjuvant treatment compared to adjuvant treatment only, but no studies have compared PD-1 monotherapy (SWOG 1801 regimen) to the PD-1/CTLA-4 combination (NADINA regimen) therapy. The SWE-NEO study aims to compare these two regimens, where the PD-1/CTLA-4 combination is potentially more effective, but also associated with more side effects.
This description comes directly from the study's public registry record.
Hildur Helgadottir, MD, PhD · +46 8-123 734 15 · hildur.helgadottir@regionstockholm.se
Roger Olofsson Bagge, Professor · +46313421000 · roger.olofsson.bagge@gu.se
Always discuss trial participation with your own doctor first.
| Sahlgrenska University Hospital | Gothenburg, Sweden | Recruiting |
| Skane University Hospital | Lund, Sweden | Recruiting |
| Karolinska University Hospital | Stockholm, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06794775